Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the prevalence of NASH is the highest in the world, liver disease has become a significant public health concern as a result of a steep increase in the prevalence of diabetes and obesity. As of today, only off-label generic drugs are prescribed to treat the condition, but we anticipate the launch and gradual but substantial uptake of novel agents—semaglutide (Novo Nordisk’s Wegovy), denifanstat (TVB-2640) (Sagimet Biosciences), and lanifibranor (Inventiva Pharma)—during the forecast period. In view of the significant unmet medical need and the absence of approved disease-modifying treatments (DMTs) for NASH, China presents significant market potential for drug developers.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 hepatologists and gastroenterologists.
Epidemiology: Diagnosed prevalence of NASH in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase 3/PR: 2 drugs; Phase 2: 10+ drugs; coverage of select preclinical and Phase 1 products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.